

Clariant Helps Deliver an AI-Enabled Hereditary Cancer Risk Platform Reaching 21 Million Patients

Clariant, a global AI-native tech company, announced today a platform that improves early detection and empowers patients to act on hereditary cancer risk.

NEW YORK, NY, UNITED STATES, April 29, 2025 /EINPresswire.com/ -- [Clariant](#), a global AI-native technology company, announced today the deployment of a hereditary cancer risk platform developed in collaboration with a leading digital health partner. The platform, which is now live across multiple healthcare ecosystems, has supported more than 21 million patient risk assessments worldwide.



Targeted at individuals with a family history of hereditary cancers—including breast, ovarian, and colorectal—the platform is designed to help patients better understand and act on their genetic risk through an accessible, digital-first experience.

“

We’re helping people make sense of complex health information and empowering them to take action.”

Harjeet Gulati

“It’s not about building another app, it’s about building trust at the moment it matters most,” said [Harjeet Gulati](#), Group Chair & CEO of Clariant.

The platform is currently in use across diverse healthcare environments in the United States, including health systems, research centers, and digital health startups. Clariant continues to support its client in scaling the solution, with a focus on deploying it in high-risk and underserved communities where early access to screening is often limited.

Clariant's engineering and UX teams helped transform a previously fragmented, technical process into a streamlined, guided user experience.

The platform includes:

- A digital assessment tool to capture detailed family and personal history
- Interactive education modules to improve patient comprehension
- Structured, patient-friendly result formats and follow-up guidance
- Secure workflows for referrals and care coordination
- Family-wide risk tracking features to support preventive outreach

Clariant worked closely with clinicians, genetic counselors, and advocacy groups during development, while also providing strategic design and engineering support throughout the product lifecycle.

Since launch, the platform has demonstrated:

- Over 21 million risk assessments completed
- A 50% increase in detection accuracy versus legacy tools
- A 94% comprehension rate among patients receiving results
- Improved referral and follow-up workflows for at-risk families

The solution is now in use across U.S. health systems, research centers, and digital health companies, with an emphasis on scaling access in under-served populations.

"With hereditary cancers on the rise, platforms like this are becoming central to population health strategy" added Harjeet Gulati.

Clariant's broader healthcare innovation portfolio includes an [AI-powered sepsis detection](#) interface that reduced ICU mortality by 18%, a chronic care mentorship platform that improved treatment adherence by 62%, and a prenatal care dashboard that helped reduce complications by 22%.

About Clariant

Clariant is a global, technology-first company built to accelerate innovation and deliver measurable outcomes across complex industries. With AI at the core, Clariant helps organizations rethink how they operate, adapt, and grow—through powerful solutions in intelligent automation, digital transformation, product engineering, and enterprise innovation. With teams across North America, Europe, Asia, and Latin America, Clariant partners with leaders in healthcare, life sciences, clean energy, and beyond to turn bold ideas into smarter systems and better futures.

Yogesh Pandey

Clariant

+91 90532 00658

yogesh.pandey@clariant.us

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/807657212>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.